Clinical Trial Update: REAL3 Trial of Efficacy of EOX With/Without Panitumumab in Previously Untreated Adv OG Cancer [Phase 3]

View source ↗

Summary

The REAL3 Phase 3 trial evaluating EOX with or without panitumumab for previously untreated advanced esophagogastric cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophagogastric Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• Epirubicin (epirubicin)
• OXALIPLATIN (Oxaliplatin)
• Panitumumab (panitumumab)

Snippet

Sponsor: Royal Marsden NHS Foundation Trust | Conditions: Oesophago-gastric Cancer | Phase 3 | Status: TERMINATED